Cargando…

Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients

PURPOSE: Tacrolimus is recommended by KDIGO Clinical Practice Guidelines as an initial therapy for the treatment of membranous nephropathy (MN). However, little is known about the factors that influence response and recurrence of the disease after tacrolimus therapy, and there are limited data regar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Shuang, Liang, Yan-Jun, Li, Zhao, Wang, Yong, Guo, Xin-Ru, Zhang, Chao-yang, Zhang, Chun, Wu, Jie, Wang, Xiao-Long, Li, Yi-Sha, Cai, Guang-Yan, Chen, Xiang-Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106312/ https://www.ncbi.nlm.nih.gov/pubmed/37077772 http://dx.doi.org/10.2147/TCRM.S399218

Ejemplares similares

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
por: Shang, Shun-Lai, et al.
Publicado: (2018)

The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy
por: Liang, Qian, et al.
Publicado: (2017)

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Tacrolimus-induced epilepsy with primary membranous nephropathy: A case report
por: Yang, Yan, et al.
Publicado: (2021)

Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy
por: Lv, Wei, et al.
Publicado: (2021)

Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
por: Wang, Qi, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
por: Lin, Wenshan, et al.
Publicado: (2019)

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
por: Cui, W., et al.
Publicado: (2017)

Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients
por: Qin, Hua-Zhang, et al.
Publicado: (2017)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study
por: Liu, Shanshan, et al.
Publicado: (2015)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
por: Zhang, Chengning, et al.
Publicado: (2020)

Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study
por: Chen, Xian, et al.
Publicado: (2023)

Tacrolimus Protects Podocytes from Apoptosis via Downregulation of TRPC6 in Diabetic Nephropathy
por: Ma, Ruixia, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis
por: Zhang, Yong, et al.
Publicado: (2018)

Electron-Dense Deposition Patterns and the Outcomes of Nephrotic Idiopathic Membranous Nephropathy Treated with Tacrolimus in Chinese Adults
por: Xiang, Xin, et al.
Publicado: (2021)

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study
por: Chen, Shasha, et al.
Publicado: (2020)

Urinary sediment miRNAs reflect tubulointerstitial damage and therapeutic response in IgA nephropathy
por: Liang, Shuang, et al.
Publicado: (2017)

Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
por: Zhao, Lijuan, et al.
Publicado: (2023)

Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy
por: Wang, Yan-Ni, et al.
Publicado: (2022)

Preparation and In Vitro Evaluation of Tacrolimus-Loaded Ethosomes
por: Li, Guiling, et al.
Publicado: (2012)

The Calcineurin Inhibitor Tacrolimus Reduces Proteinuria in Membranous Nephropathy Accompanied by a Decrease in Angiopoietin-Like-4
por: Peng, Lei, et al.
Publicado: (2014)

Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials
por: Huang, Haiting, et al.
Publicado: (2021)

High exposure to tacrolimus is associated with spontaneous remission of recurrent membranous nephropathy after kidney transplantation
por: Buxeda, Anna, et al.
Publicado: (2023)

Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy
por: Hu, Tingyang, et al.
Publicado: (2018)

The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy ——protocol of a multicenter, randomized control trial (SQ-AUTUMN)
por: Li, Chuang, et al.
Publicado: (2023)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Membranous Nephropathy Associated with Tuberculosis
por: Shang, Ming-Hua, et al.
Publicado: (2016)

Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2021)

Treatment of HIV-Associated Lupus-like Membranous Nephropathy with Tacrolimus: A Case Report and Review of the Literature
por: Kofotolios, Ioannis, et al.
Publicado: (2023)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
por: Zhong, Hongzhen, et al.
Publicado: (2020)

Selection of urinary sediment miRNAs as specific biomarkers of IgA nephropathy
por: Duan, Zhi-Yu, et al.
Publicado: (2016)

Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome?
por: He, Jia-Wei, et al.
Publicado: (2022)

The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study
por: Liu, Yanan, et al.
Publicado: (2023)

U6 can be used as a housekeeping gene for urinary sediment miRNA studies of IgA nephropathy
por: Duan, Zhi-Yu, et al.
Publicado: (2018)

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
por: Lin, Shujun, et al.
Publicado: (2019)

Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide
por: Ramachandran, Raja, et al.
Publicado: (2017)

Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis
por: Song, Yu-Huan, et al.
Publicado: (2017)

microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis
por: Yang, Min-Hui, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9v35vl0kkqln78nh8898m7t90n